For Morbidly Obese Patients, Bariatric Surgery is an Increasingly Attractive Option after More Traditional Weight Loss Methods Have Failed.DUBLIN, ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c31676) has announced the addition of "Impact of Bariatric Surgeries Bariatric Surgery Definition Bariatric surgery promotes weight loss by changing the digestive system's anatomy, limiting the amount of food that can be eaten and digested. on the Obesity Pharmaceutical Market" to their offering. For morbidly mor·bid adj. 1. a. Of, relating to, or caused by disease; pathological or diseased. b. Psychologically unhealthy or unwholesome: obese patients, bariatric surgery is an increasingly attractive option after more traditional weight loss methods have failed. The lack of long-term efficacy and the modest weight loss associated with currently marketed anti-obesity drugs--particularly among morbidly obese patients--do not make them an attractive therapeutic option. As a result, drug prescriptions have declined over the past few years, and the number of annual bariatric surgeries has risen. The issue for pharmaceutical companies is how this growing recognition of bariatric surgery will affect the market for anti-obesity drugs Anti-obesity drugs include all pharmacological treatments intended to reduce or control weight. Because these drugs are intended to alter one of the fundamental processes of the human body, anti-obesity drugs are medically prescribed only in cases of morbid obesity, where weight . This Decision Resources report reviews major considerations in the treatment of obesity, including its classification as a disease, and where pharmaceuticals and bariatric surgery fit into the therapeutic algorithm in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. . The report provides an overview of bariatric surgeries, and discusses promising emerging therapies in the treatment of obesity and the impact bariatric surgery is expected to have on the overall pharmaceutical market in light of the expected launch of Sanofi-Aventiss rimonabant (Acomplia). Although sales of anti-obesity drugs have declined in recent years, the Years, The the seven decades of Eleanor Pargiter’s life. [Br. Lit.: Benét, 1109] See : Time number of bariatric surgeries is on the rise, fueled by the potential for significant weight loss and safer procedures. However, the surgeries will remain a third-line therapy third-line therapy Any alternative to conventional–surgery, chemotherapy or RT for malignancy. Cf Unproven forms of cancer therapy. because of the invasive nature of the treatment and the lifestyle aspect of the disease. No improvements in surgical procedures Surgical procedures have long and possibly daunting names. The meaning of many surgical procedure names can often be understood if the name is broken into parts. For example in splenectomy, "ectomy" is a suffix meaning the removal of a part of the body. "Splene-" means spleen. are likely to position bariatric surgery as a replacement for lifestyle interventions and drug therapies. The anti-obesity market is awaiting the arrival of rimonabant (Sanofi-Aventis's Acomplia), a potential blockbuster that may postpone the need for bariatric surgeries, particularly in class II obese patients who would otherwise be eligible for surgical intervention. This novel therapy will reduce the impact of bariatric surgeries on the obesity pharmaceutical market provided it meets expectations. Vast commercial opportunities exist for a more efficacious ef·fi·ca·cious adj. Producing or capable of producing a desired effect. See Synonyms at effective. [From Latin effic treatment for obesity. The increasing prevalence of obesity and the introduction of novel agents such as rimonabant will drive the growth of the U.S. obesity market from $315 million in 2003 to more than $1.7 billion in 2013. The treatment of obesity represents a dilemma for third-party payers. The recognition of obesity as a disease, the fact that obesity is a major risk factor for many long-term chronic health conditions, and pressure from lawmakers have prompted some third-party payers to begin reimbursing for bariatric surgeries. However, the expected rise in obesity (to 88 million individuals by 2013) means that continued reimbursement Reimbursement Payment made to someone for out-of-pocket expenses has incurred. for obesity treatment may represent a financial impracticality for these companies. Key topics covered: --A Changing View of Obesity and Anti-Obesity Therapy --Obesity: Why Is It a Disease? --Treatment of Obesity in the United States Obesity has been cited as a major and increasing health issue in the United States in recent decades. While many industrialized countries have experienced similar increases, American obesity rates lead the world with 64% of adults being overweight and almost a quarter being obese. --Overview of Bariatric Surgeries --The U.S. Obesity Market Companies Mentioned --Sanofi-Aventis's --Roche --Abbott --UCB --GlaxoSmithKline --Wyeth For more information visit http://www.researchandmarkets.com/reports/c31676 Source: Decision Resources, Inc. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion